Acetazolamide Reduces Retinal Inner Nuclear Layer Thickness in Microcystic Macular Edema Secondary to Optic Neuropathy
| Autor: | Nathalie Voide, François-Xavier Borruat, Muriel Dysli, Mathias Abegg |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty genetic structures Macular Edema Retina Optic neuropathy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Ophthalmology Optic Nerve Diseases medicine Humans Diuretics Macular edema Aged Retrospective Studies Water transport business.industry Retinal Middle Aged medicine.disease Layer thickness eye diseases Acetazolamide medicine.anatomical_structure Neurology chemistry Inner nuclear layer 030221 ophthalmology & optometry Female sense organs Neurology (clinical) business 030217 neurology & neurosurgery After treatment Tomography Optical Coherence medicine.drug |
| Zdroj: | European neurology. 79(3-4) |
| ISSN: | 1421-9913 |
| Popis: | Optic neuropathy (ON) is commonly complicated by microcystic macular edema (MME), that is, small vertical cystoid spaces in the inner nuclear layer (INL) of the macula. We performed a retrospective consecutive case series of 14 eyes from 11 patients with ON and MME that were treated with oral acetazolamide, acting on cellular water transport. Contralateral eyes without MME were used as controls. Segmentation of images obtained with OCT was used to determine changes of individual retinal layer thickness during treatment. Retinal INL thickness consistently decreased in all eyes after 2–3 weeks of treatment. Recurrence of MME was observed after treatment cessation. No significant change of retinal thickness was found in contralateral unaffected eyes. Visual function did not change with treatment. Acetazolamide significantly improved the MME in eyes with ON. However, visual function did not. Acetazolamide is a treatment option for MME associated with ON but without an impact on the visual function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|